

## References

1. US Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients guidance for industry, food and drug administration staff, and other stakeholders. FDA; 2022. Accessed May 24, 2024. <https://www.fda.gov/media/131230/download>
2. European Medicines Agency. ICH guideline E8 (R1) on general considerations for clinical studies. EMA; 2022. Accessed May 24, 2024. [https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-e8-r1-general-considerations-clinical-studies\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-e8-r1-general-considerations-clinical-studies_en.pdf)
3. Wesnes KA, Garratt C, Wickens M, Gudgeon A, Oliver S. Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. *Br J Clin Pharmacol*. 2000;49(2):110-117.
4. Van Harten J, Stevens L, Raghoobar M, Holland R, Wesnes K, Cournot A. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. *Clin Pharmacol Ther*. 1992;52:427-435.
5. Matsui T, Nakaaki S, Murata Y, et al. Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the Quality of Life–Alzheimer's Disease Scale. *Dement Geriatr Cogn Disord*. 2006;21(3):182-191.
6. Neuren Pharmaceuticals. Clinical Trials Update. 2007.